Originally published as JCO Early Release 10.1200/JCO.2008.17.1777 on December 1 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tarhini, A. A. Articles by Kirkwood, J. M. Search for Related Content PubMed PubMed Citation Articles by Tarhini, A. A. Articles by Kirkwood, J. M. Social Bookmarking                            What's this?

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

Ahmad A. Tarhini, Joseph Stuckert, Sandra Lee, Cindy Sander, John M. Kirkwood

From the University of Pittsburgh Cancer Institute, Pittsburgh, PA; and Dana-Farber Cancer Institute, Boston, MA

Corresponding author: John M. Kirkwood, MD, University of Pittsburgh Cancer Institute, 5117 Centre Ave, Ste 1.32, Pittsburgh, PA 15213; e-mail: kirkwoodjm{at}upmc.edu

Purpose We evaluated adjuvant trial E1694 to more precisely define the prognostic significance of serum S100B in patients with high-risk resected melanoma.

Patients and Methods Sera from 670 E1694 patients banked at baseline and three additional time points were tested for S100B protein using chemiluminescence.

Results S100B testing results showed that the higher the S100B level is, the higher the risk of relapse and death, regardless of the cutoff value. Univariate analysis showed that baseline S100B 0.15 µg/L is significantly correlated with overall survival (OS; P = .01). Multivariate analysis was performed adjusting for significant prognostic factors (ulceration and lymph node status) and treatment. Baseline S100B was a significant prognostic factor for survival (hazard ratio = 1.39; 95% CI, 1.01 to 1.92; P = .043). S100B values measured at later time points over 1 year were also demonstrated to be significant prognostic factors for relapse-free survival (RFS) and OS. Lower S100B values at baseline and during follow-up were associated with longer survival. A changing S100B from low at baseline to high on follow-up seemed to be associated with the worst RFS and OS.

Conclusion For patients with high-risk surgically resected melanoma, a high baseline or increasing serum S100B is an independent prognostic marker of risk for mortality that may allow us to refine the application of adjuvant therapy in the future.

published online ahead of print at www.jco.org on December 1, 2008

Both A.A.T. and J.S. contributed equally to this work.

Supported by DiaSorin.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?